Key result
ICIs and CAR-T therapies induce significant cardiotoxicity requiring early management with corticosteroids and tocilizumab.
Why the study?
Despite their efficacy in cancer treatment, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies can induce cardiotoxicity, presenting significant clinical challenges.
What are the mechanisms, risk factors, and management strategies for cardiotoxicity induced by immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy?
Population
Studies focusing on cardiotoxicity related to immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy
Design
Narrative review
Authors
Loading...
May warrant vigilance for cardiotoxicity with these therapies; leaves open prospective validation of management strategies.
What are the mechanisms, risk factors, and management strategies for cardiotoxicity induced by immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy?
Early diagnosis and collaborative management are essential to mitigate the cardiovascular risks associated with immune checkpoint inhibitors and CAR T-cell therapy, particularly in peri-operative settings.
Malode et al. (2025) conducted a review in Cardiotoxicity from immunotherapy. Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy was evaluated. Immune checkpoint inhibitors and CAR T-cell therapies can induce significant cardiotoxicity, requiring early diagnosis and management with corticosteroids and tocilizumab.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: